-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Tamoxifen, editor of WuXi AppTec's content team, has been clinically used for more than 40 years.
This is the first drug approved by the U.
S.
FDA for breast cancer prevention in high-risk women, which can reduce the risk of breast cancer by as much as 40%.
Among all four breast cancer prevention drugs approved so far, tamoxifen is also the only drug approved by the U.
S.
FDA Approved drugs for breast cancer prevention in premenopausal women at the same time, and other drug indications are for postmenopausal use.
At the same time, tamoxifen is also approved for the adjuvant treatment of breast cancer, which can significantly reduce the risk of postoperative recurrence.
The typical preventive medication cycle of tamoxifen is usually 5 years and is taken once a day.
However, for many women, the side effects of tamoxifen are also a problem.
Menopausal symptoms such as flushing, sweating, insomnia and various gynecological adverse reactions lead to about half of patients who take tamoxifen to prevent recurrence after surgery.
About half of the patients who take tamoxifen after surgery may discontinue treatment; women who are healthy but with high genetic risk do not take many preventive drugs.
.
Now, this problem is expected to be improved by adjusting the dose to promote tamoxifen to play a better role in the prevention and treatment of breast cancer.
A study led by scholars from the Karolinska Institutet, a well-known medical school, showed that for premenopausal women, a much lower dose than the standard dose can bring good results with fewer adverse reactions.
The research results were recently published in the ASCO journal "Journal of Clinical Oncology" (Journal of Clinical Oncology).
Screenshot source: Journal of Clinical Oncology.
This study is based on the Swedish mammography (X-ray) screening project and conducted a randomized double-blind placebo-controlled trial to compare different doses of tamoxifen in reducing breast density and reducing symptoms The aim is to find the lowest effective dose with fewer side effects. Tamoxifen is a selective estrogen receptor modulator that can block estrogen in breast cancer cells, and estrogen promotes the growth of breast cancer cells.
Previous studies have proved that tamoxifen can reduce the breast density of women during mammography examination, and the changes in mammography examination can be used as a surrogate indicator of tamoxifen treatment response.
The study recruited 1439 women aged 40-74 from October 1, 2016 to September 30, 2019, including 566 premenopausal women and 873 postmenopausal women.
The subjects were randomized to receive 1 mg, 2.
5 mg, 5 mg, 10 mg, 20 mg tamoxifen, or placebo.
Among them, 20mg is the standard dose of tamoxifen.
The mammography data before and after the 6-month treatment showed that in premenopausal women, the reduction in mammary density in the 2.
5 mg, 5 mg, and 10 mg tamoxifen treatment group was the same as that in the 20 mg standard dose group (median reduction 10.
1%) )similar.
At the same time, compared with the 20 mg standard dose group, severe vasomotor symptoms (such as hot flashes, cold sweats, and night sweats) in the 2.
5 mg, 5 mg, and 10 mg groups were reduced by about 50%.
The lead researcher, Professor Per Hall of the Karolinska Institute pointed out: "Reducing the dose of the drug may increase the number of patients who complete the treatment.
" Image source: 123RF Next, the research team will further verify whether 2.
5 mg of tamoxifen is indeed true Can reduce the risk of breast cancer, including the first onset and recurrence after treatment.
According to the latest data from the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer has surpassed lung cancer to become the most common new cancer in the world.
In 2020, 1 out of 8 newly diagnosed patients worldwide is a breast cancer patient.
In China, breast cancer is also the most common new cancer among women.
It is hoped that continuous research on this classic breast cancer preventive drug can help more women and patients have the opportunity to benefit from it, and promote the journey of breast cancer prevention further.
Related reading JAMA: Drugs to prevent breast cancer, which factors should be weighed, and how to choose the four drugs? BMJ: Make it simple! For early breast cancer, one intraoperative targeted radiotherapy is enough? Uti Delong was approved for listing in China: new opportunities for advanced breast cancer treatment, recommended by CSCO guidelines! "The Lancet-Oncology": Led by Professor Xu Binghe, the Chinese innovative drug pyrrotinib for the second-line treatment of HER2-positive breast cancer is again supported! Source of title picture: 123RF reference materials[1] Mikael Eriksson, et al.
, (2021).
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Journal of Clinical Oncology, DOI: 10.
1200/JCO.
20.
02598[2] Lower dose of estrogen receptor modulator seems to reduce risk of breast cancer.
Retrieved March 22, 2021, from https://medicalxpress.
com/news/2021-03-dose-estrogen-receptor-modulator-breast.
html[3] Tamoxifen and Raloxifene for Lowering Breast Cancer Risk.
Retrieved March 22, 2021, from .
html Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
This is the first drug approved by the U.
S.
FDA for breast cancer prevention in high-risk women, which can reduce the risk of breast cancer by as much as 40%.
Among all four breast cancer prevention drugs approved so far, tamoxifen is also the only drug approved by the U.
S.
FDA Approved drugs for breast cancer prevention in premenopausal women at the same time, and other drug indications are for postmenopausal use.
At the same time, tamoxifen is also approved for the adjuvant treatment of breast cancer, which can significantly reduce the risk of postoperative recurrence.
The typical preventive medication cycle of tamoxifen is usually 5 years and is taken once a day.
However, for many women, the side effects of tamoxifen are also a problem.
Menopausal symptoms such as flushing, sweating, insomnia and various gynecological adverse reactions lead to about half of patients who take tamoxifen to prevent recurrence after surgery.
About half of the patients who take tamoxifen after surgery may discontinue treatment; women who are healthy but with high genetic risk do not take many preventive drugs.
.
Now, this problem is expected to be improved by adjusting the dose to promote tamoxifen to play a better role in the prevention and treatment of breast cancer.
A study led by scholars from the Karolinska Institutet, a well-known medical school, showed that for premenopausal women, a much lower dose than the standard dose can bring good results with fewer adverse reactions.
The research results were recently published in the ASCO journal "Journal of Clinical Oncology" (Journal of Clinical Oncology).
Screenshot source: Journal of Clinical Oncology.
This study is based on the Swedish mammography (X-ray) screening project and conducted a randomized double-blind placebo-controlled trial to compare different doses of tamoxifen in reducing breast density and reducing symptoms The aim is to find the lowest effective dose with fewer side effects. Tamoxifen is a selective estrogen receptor modulator that can block estrogen in breast cancer cells, and estrogen promotes the growth of breast cancer cells.
Previous studies have proved that tamoxifen can reduce the breast density of women during mammography examination, and the changes in mammography examination can be used as a surrogate indicator of tamoxifen treatment response.
The study recruited 1439 women aged 40-74 from October 1, 2016 to September 30, 2019, including 566 premenopausal women and 873 postmenopausal women.
The subjects were randomized to receive 1 mg, 2.
5 mg, 5 mg, 10 mg, 20 mg tamoxifen, or placebo.
Among them, 20mg is the standard dose of tamoxifen.
The mammography data before and after the 6-month treatment showed that in premenopausal women, the reduction in mammary density in the 2.
5 mg, 5 mg, and 10 mg tamoxifen treatment group was the same as that in the 20 mg standard dose group (median reduction 10.
1%) )similar.
At the same time, compared with the 20 mg standard dose group, severe vasomotor symptoms (such as hot flashes, cold sweats, and night sweats) in the 2.
5 mg, 5 mg, and 10 mg groups were reduced by about 50%.
The lead researcher, Professor Per Hall of the Karolinska Institute pointed out: "Reducing the dose of the drug may increase the number of patients who complete the treatment.
" Image source: 123RF Next, the research team will further verify whether 2.
5 mg of tamoxifen is indeed true Can reduce the risk of breast cancer, including the first onset and recurrence after treatment.
According to the latest data from the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer has surpassed lung cancer to become the most common new cancer in the world.
In 2020, 1 out of 8 newly diagnosed patients worldwide is a breast cancer patient.
In China, breast cancer is also the most common new cancer among women.
It is hoped that continuous research on this classic breast cancer preventive drug can help more women and patients have the opportunity to benefit from it, and promote the journey of breast cancer prevention further.
Related reading JAMA: Drugs to prevent breast cancer, which factors should be weighed, and how to choose the four drugs? BMJ: Make it simple! For early breast cancer, one intraoperative targeted radiotherapy is enough? Uti Delong was approved for listing in China: new opportunities for advanced breast cancer treatment, recommended by CSCO guidelines! "The Lancet-Oncology": Led by Professor Xu Binghe, the Chinese innovative drug pyrrotinib for the second-line treatment of HER2-positive breast cancer is again supported! Source of title picture: 123RF reference materials[1] Mikael Eriksson, et al.
, (2021).
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Journal of Clinical Oncology, DOI: 10.
1200/JCO.
20.
02598[2] Lower dose of estrogen receptor modulator seems to reduce risk of breast cancer.
Retrieved March 22, 2021, from https://medicalxpress.
com/news/2021-03-dose-estrogen-receptor-modulator-breast.
html[3] Tamoxifen and Raloxifene for Lowering Breast Cancer Risk.
Retrieved March 22, 2021, from .
html Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
